Abstract
In this chapter, we illustrate how evidence about treatments’ benefits and harms can be integrated to enable rational decision-making even under considerable clinical uncertainty.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
See also Appendix, Section B2. In the case when diagnosis (clinical event- See glossary) is not certain (i.e., 0 < p < 1) and outcomes are expressed in binary (yes/no) terms and no further dx test is available, it can be shown that equivalent formula shown in the equation #12 can be obtained if we are interested in determining the threshold probability of event (p):
$${p}_{t}=\frac{{{\text{RV}}_{H}\cdot H}_{rx}}{{\text{RRR}}}$$
References
Cornelissen JJ, Van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al (2007) Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109(9):3658–3666
Djulbegovic B, Hozo I, Lyman GH. Linking evidence-based medicine therapeutic summary measures to clinical decision analysis. MedGen: Medicine. 2000;2(1):E6.
Djulbegovic B, van den Ende J, Hamm RM, Mayrhofer T, Hozo I, Pauker SG (2015) When is rational to order a diagnostic test, or prescribe treatment: the threshold model as an explanation of practice variation. Eur J Clin Invest 45(5):485–493
Djulbegovic B, Hozo I, Mayrhofer T, van den Ende J, Guyatt G (2019) The threshold model revisited. J Eval Clin Pract 25(2):186–195
Hu X, Wang B, Chen Q, Huang A, Fu W, Liu L et al (2021) A clinical prediction model identifies a subgroup with inferior survival within intermediate risk acute myeloid leukemia. J Cancer 12(16):4912–4923
Kahale LA, Matar CF, Tsolakian I, Hakoum MB, Barba M, Yosuico VE, et al. Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database of Systematic Reviews. 2021(10).
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, The Journal of the American Society of Hematology. 111(10):4902–4907
Li A, Garcia DA, Lyman GH, Carrier M (2019) Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res 173:158–163
Pabinger I, van Es N, Heinze G, Posch F, Riedl J, Reitter E-M et al (2018) A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. The Lancet Haematology. 5(7):e289–e298
Pauker SG, Kassirer JP (1975) Therapeutic decision making: a cost-benefit analysis. N Engl J Med 293(5):229–234
Wells PS, Anderson DR, Rodger M et al (2001) Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med 135(2):98–107
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Djulbegovic, B., Hozo, I. (2023). Making Decisions When No Further Diagnostic Testing is Available. In: Threshold Decision-making in Clinical Medicine. Cancer Treatment and Research, vol 189. Springer, Cham. https://doi.org/10.1007/978-3-031-37993-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-031-37993-2_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-37992-5
Online ISBN: 978-3-031-37993-2
eBook Packages: MedicineMedicine (R0)